Notes
The exact type of chemotherapeutic regimen which the patient received was not described.
Reference
Tampellini M, et al. Bioequivalence of branded and generic oxaliplatin: From preclinical assessment to clinical incidence of hypersensitivity reactions. Anticancer Research 36: 5163-5170, No. 10, Oct 2016. Available from: URL: http://doi.org/10.21873/anticanres.11086 - Italy
Rights and permissions
About this article
Cite this article
Oxaliplatin. Reactions Weekly 1633, 572 (2017). https://doi.org/10.1007/s40278-017-24839-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-24839-y